ESC 365 - A deeper dive into key ODYSSEY OUTCOMES results and their impact on patient management.

ESC Premium Access

A deeper dive into key ODYSSEY OUTCOMES results and their impact on patient management.

Session: From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition

Topic: Lipids

Speaker: Professor G. Schwartz (Aurora, US)

Sponsored by Sanofi and Regeneron

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Gregory Schwartz

University of Colorado School of Medicine, Aurora (United States of America)

2 presentations

0 follower

2 more presentations in this session

From identification of high CV risk patients to treatment with PCSK9i: learnings from ODYSSEY OUTCOMES.

Speaker: Professor A. Zeiher (Frankfurt, DE)

Interaction with the audience

Speaker: Professor A. Zeiher (Frankfurt, DE)

Access the full session

From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition

Speakers: Professor G. Schwartz, Professor A. Zeiher, Professor A. Zeiher

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources